


CLAIMS

1. A chemical compound of formula (I):



(I)

wherein:

R₁ and R₂ are independently selected from hydrogen and alkyl;

R₃ is alkyl;

R₄, R₆ and R₇ are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, alkylsulfonyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl;

R₅ is selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, alkylsulfonyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and

A is a 5- or 6-membered partially unsaturated or aromatic heterocyclic ring or a 5- or 6- membered partially unsaturated carbocyclic ring,

wherein if A is a 6-membered partially unsaturated carbocyclic ring then at least one of R₄ to R₇ is other than hydrogen,

and pharmaceutically acceptable salts, addition compounds and prodrugs thereof.

2. A compound according to claim 1 wherein R₁ and R₂ are selected from hydrogen and lower alkyl.

3. A compound according to claim 1 wherein R₁ and R₂ are hydrogen.

4. A compound according to claim 1, 2 or 3 wherein R₃ is lower alkyl.

5. A compound according to claim 1, 2 or 3 wherein R₃ is methyl.
6. A compound according to any preceding claim wherein R₄ is selected from hydrogen, halogen, alkyl and alkoxy.
- 5 7. A compound according to any preceding claim wherein R₄ is hydrogen.
- 10 8. A compound according to any preceding claim wherein R₆ is selected from hydrogen and halogen.
- 15 9. A compound according to any preceding claim wherein R₇ is selected from hydrogen, halogen and alkoxy.
10. A compound according to any preceding claim wherein A is a 5- membered ring.
11. A compound according to any preceding claim wherein A is partially unsaturated.
12. A compound according to any preceding claim wherein A contains a heteroatom selected from N, O and S.
- 20 13. A compound according to any of claims 1 to 9 wherein A is a 5- membered partially unsaturated carbocyclic ring, a 5- membered partially unsaturated or aromatic heterocyclic ring or a 6- membered partially unsaturated carbocyclic ring.
- 25 14. A compound according to any of claims 1 to 9 wherein A is selected from cyclopentenyl, cyclohexenyl, thiacyclohexenyl and thienyl.
- 30 15. A compound according to claim 1 which is selected from (S)-1-(7,8-difluoro-1,2,3,4-tetrahydrocyclopent[b]indol-4-yl)-2-propylamine, (S)-1-(7-fluoro-1,2,3,4-tetrahydrocyclopent[b]indol-4-yl)-2-propylamine, (S)-1-(8-chloro-1,2,3,4-tetrahydrocyclopent[b]indol-4-yl)-2-propylamine, (S)-1-(6-methoxy-1,2,3,4-tetrahydrocyclopent[b]indol-4-yl)-2-propylamine, (S)-1-(7-fluoro-6-methoxy-1,2,3,4-tetrahydrocyclopent[b]indol-4-yl)-2-propylamine, (S)-1-(7-fluoro-8-

SUB
A2 cont'd.

SUB
A2 cont'd

methoxy-1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine, (*S*)-1-(8-chloro-7-fluoro-1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine, (*S*)-1-(1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine, (*R*)-1-(1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine.

5

16. A compound of formula (I) as set out in any one of claims 1 to 15 for use in therapy.

10

17. The use of a compound of formula (I) as set out in any of claims 1 to 15 in the manufacture of a medicament for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea.

15

18. A use according to claim 17 wherein the disorders of the central nervous system are selected from depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioural disorders, behavioural disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

20

SUB
A3

19. A use according to claim 17 wherein the damage to the central nervous system is by trauma, stroke, neurodegenerative diseases or toxic or infective CNS diseases.

25

20. A use according to claim 19 wherein said toxic or infective CNS disease is encephalitis or meningitis.

30

21. A use according to claim 17 wherein the cardiovascular disorder is thrombosis.

22. A use according to claim 17 wherein the gastrointestinal disorder is dysfunction of gastrointestinal motility.

23. A use according to claim 17 wherein said medicament is for the treatment of obesity.

5 24. A use according to any one of claims 17 to 23 wherein said treatment is prophylactic treatment.

SUB 10 AY
25. A method of treatment of any of the disorders set out in claims 17 to 22 comprising administering to a patient in need of such treatment an effective dose of a compound of formula (I) as set out in any one of claims 1 to 15.

26. A method of treatment according to claim 25 wherein said disorder is obesity.

SUB 15
27. A method according to claim 25 or 26 wherein said treatment is prophylactic treatment.

28. A method of preparing a compound of formula (I) as set out in any one of claims 1 to 15.

20 29. A pharmaceutical composition comprising a compound of formula (I) as set out in any one of claims 1 to 15 in combination with a pharmaceutically acceptable carrier or excipient.

SUB 25
30. A method of making a composition according to claim 29 comprising combining a compound of formula (I) as set out in any one of claims 1 to 15 with a pharmaceutically acceptable carrier or excipient.